Estrella Immunopharma Inc
For the period ended Jun 30, 2024. Filed Sep 27, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Sep 27, 2024
ESLA$0.75+45.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity (Deficit)
| Series A Preferred Stock · Series AA Preferred Stock · Common Stock · Treasury · Additional Paid-in · Accumulated · Total Stockholders’ Equity | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares* · Amount · Shares* · Amount · Shares* · Amount · Stock · Capital · Deficit · (Deficit) | |||||||||||||
| Balance, July 1, 2022 | 5,000,000 | $5,000,000 | 105,000,000 | $ | - | 176,000 | $18 | $ | - | $34,290 | $(1,074,151) | $(1,039,843) | |
| Recapitalization | (3,796,305) | - | (79,722,409) | - | (133,630) | (14) | - | 14 | - | - | |||
| Balance, July 1, 2022 | 1,203,695 | 5,000,000 | 25,277,591 | - | 42,370 | 4 | - | 34,304 | (1,074,151) | (1,039,843) | |||
| Vesting of early exercised stock options | - | - | - | - | 935,873 | 94 | - | 2,006 | - | 2,100 | |||
| Stock-based compensation | - | - | - | - | - | - | - | 409,595 | - | 409,595 | |||
| Net loss | - | - | - | - | - | - | - | (11,114,402) | (11,114,402) | ||||
| Balance, June 30, 2023 | 1,203,695 | 5,000,000 | 25,277,591 | - | 978,243 | 98 | $ | - | 445,905 | (12,188,553) | (11,742,550) | ||
| Issuance of series A preferred stock | 2,407,390 | 9,750,000 | - | - | - | - | - | - | - | - | |||
| Conversion of series A and series AA preferred stock into common stock | (3,611,085) | (14,750,000) | (25,277,591) | - | 28,888,675 | 2,889 | - | 14,747,111 | - | 14,750,000 | |||
| Vesting of early exercised stock options | - | - | - | - | 2,633,082 | 263 | - | 12,462 | - | 12,725 | |||
| Stock-based compensation | - | - | - | - | - | - | - | 1,194,653 | - | 1,194,653 | |||
| Issuance of common stock for PIPE investment | - | - | - | - | 1,000,000 | 100 | - | 9,999,900 | - | 10,000,000 | |||
| Issuance of common stock upon completion of business combination | - | - | - | - | 1,701,232 | 170 | - | (474,147) | - | (473,977) | |||
| Transactions cost | - | - | - | - | - | - | - | (1,801,200) | - | (1,801,200) | |||
| Issuance of common stock for PIPE investment | - | - | - | - | 1,409,638 | 141 | - | (141) | - | - | |||
| Purchase of treasury stock | - | - | - | - | - | - | (354,440) | - | - | (354,440) | |||
| Net loss | - | - | - | - | - | - | - | - | (7,311,723) | (7,311,723) | |||
| Balance, June 30, 2024 | - | $ | - | - | $ | - | 36,610,870 | $3,661 | $(354,440) | $24,124,543 | $(19,500,276) | $4,273,488 | |
| * | Giving retroactive effect to reverse recapitalization effected on September 29, 2023 to reflect exchange ratio of approximately 0.2407 as described in Note 3 |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.